SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
22 févr. 2023 08h00 HE
|
SciSparc Ltd
Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
17 févr. 2023 08h00 HE
|
SciSparc Ltd
MitoCareX established its initial cloud-based computing infrastructure TEL AVIV, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty...
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
15 févr. 2023 08h30 HE
|
SciSparc Ltd
Clearmind’s applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc’s CannAmide™ and classical psychedelics ...
SciSparc Announces Corporate Restructuring plan
25 janv. 2023 08h30 HE
|
SciSparc Ltd
SciSparc will examine the possibility of a public listing for its pharmaceutical activity while retaining a controlling interest TEL AVIV, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- SciSparc...
SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares
23 janv. 2023 09h20 HE
|
SciSparc Ltd
The Company is expected to evaluate alternatives to address potential short sales issue TEL AVIV, Israel, Jan. 23, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
18 janv. 2023 07h30 HE
|
SciSparc Ltd
The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 18, 2023 (GLOBE...
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
17 janv. 2023 08h30 HE
|
SciSparc Ltd
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process. ...
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
09 janv. 2023 08h30 HE
|
SciSparc Ltd
Ethics Committee and Israeli Ministry of Health approvals already received for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) -- ...
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
05 janv. 2023 09h00 HE
|
SciSparc Ltd
SciSparc and Clearmind’s collaboration continues to yield positive outcomes, the latest with Clearmind results for treating obesity and its related metabolic disorders TEL AVIV, Israel, Jan. ...
SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
14 déc. 2022 09h15 HE
|
SciSparc Ltd
TEL AVIV, Israel, Dec. 14, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...